EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Rakovina Therapeutics's enterprise value is C$8.54 Mil.
Rakovina Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was C$-1.97 Mil. Therefore, Rakovina Therapeutics's EV-to-EBITDA for today is -4.33.
The historical rank and industry rank for Rakovina Therapeutics's EV-to-EBITDA or its related term are showing as below:
TSXV:RKV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -93.93 Med: 0 Max: 0
Current: -4.33
TSXV:RKV's EV-to-EBITDA is ranked worse than 100% of 456
companies
in the Biotechnology industry
Industry Median: 8.71
vs TSXV:RKV: -4.33
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Rakovina Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Rakovina Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rakovina Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Rakovina Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rakovina Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Rakovina Therapeutics's EV-to-EBITDA falls into.
Rakovina Therapeutics's current Enterprise Value is C$8.54 Mil.
Rakovina Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Rakovina Therapeutics's PE Ratio for today is calculated as:
Rakovina Therapeutics's share price for today is C$0.105.
Rakovina Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Rakovina Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Rakovina Therapeutics (TSXV:RKV) Business Description
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some f its products in the pipeline include kt-2000 Next Generation PARP-inhibitors, kt-3000 Dual Action DDR-inhibitors, and kt-4000 DNA Damaging DDR-inhibitors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:RKV has been successfully added to your 